What We're Reading: Page 213
Industry reads hand-picked by our editors
Oct 30, 2019
-
C&EN
Custom CRISPR therapies could be closer than you think
-
McClatchy DC
Veterans looking for answers as new data shows rise in cancers over two decades of war
-
Reuters
Ex-FDA chief Gottlieb sees investment opportunity in 'unloved' antibiotics
-
STAT
The cancer in cancer medicine: pharma money paid to doctors
Oct 29, 2019
-
The San Diego Union-Tribune
A cancer drug's journey: Hope found, then lost, then found again
-
STAT
Axovant CEO David Hung is back — leading a cancer biotech
-
The New York TImes
Is Crispr the Next Antibiotic?
-
FierceBiotech
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Oct 28, 2019
-
The Boston Globe
As his Alzheimer's looms, Charles and Pam Ogletree take one last walk in love
-
The Wall Street Journal
Intraparty Disputes Dim Outlook for Drug-Price Legislation
-
The New York Times
Scientists Were Hunting for the Next Ebola. Now the U.S. Has Cut Off Their Funding.
-
Bloomberg
Mylan CEO Bresch to Get $30.8 Million Payout After Pfizer Deal
Oct 25, 2019
-
Reuters
Biogen's secret campaign to bring its Alzheimer's drug back from the ashes
-
Kaiser Health News
Pharma sells states on ‘Netflix Model’ to wipe out hep C. But at what price?
-
Bloomberg
China's $132 billion market pushes big pharma into uncharted territory
-
San Francisco Business Times
As Stripe grabs big South San Francisco lease, biotech loses space to tech
Oct 24, 2019
Oct 23, 2019
-
Reuters
Johnson & Johnson CEO testified Baby Powder was safe 13 days before FDA bombshell
-
STAT
Alzheimer's patients in Biogen trial press for new access to treatment
-
Bloomberg
China Drugmaking Giant Says Cheap Meds Stymie Pharma's Future
-
The Wall Street Journal
Advice to Give Women Blood Thinners After C-Sections Draws Fire
Previous
